ALK mutations are approximately 3–7% of all lung tumors, and rearrangement in echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) is the most common ALK rearrangement seen in NSCLC patients [76,77,78]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.